Optimisation of grafted phosphorylcholine (cas 107-73-3)-based polymer on additively manufactured titanium substrate for hip arthroplasty
-
Add time:08/23/2019 Source:sciencedirect.com
Despite the tremendous acceptance of additively manufactured (AM) Titanium alloys (Ti6Al4V) in the field of biomedical engineering, the high surface roughness due to partially-melted particles (fabricated in selective laser melting (SLM) process), limits their uses as hip implants. The objective of this study, therefore, is to modify the SLM fabricated Ti6Al4V implant interfaces with 2-Methacryloyloxyethyl phosphorylcholine (MPC) polymer, in the hope of enhancing surface properties and preventing the attachment of the cell simultaneously without affecting the mechanical properties significantly. Three different monomer concentrations were examined to determine the influence of monomer concentrations on polymerisation rate, chain length, and surface properties of the implants. Samples grafted with 0.6 M monomer concentration showed more uniform surface and less surface roughness in comparison with other samples and untreated Ti6Al4V surfaces. 0.6 M monomer concentration was found to be the best option for grafting PMPC to the hip implant interfaces because of its improved surface morphology, surface roughness, polymerisation rate, penetration depth and hardness results. Moreover, cell study on optimal surfaces revealed that PMPC grafted surfaces prevent the implant interfaces from uncontrollable cell attachment which is of utmost importance in smoothing the motion of the hip implant under cyclic loading. Overall, the PMPC grafting demonstrated the potentiality of its application on SLM Ti6Al4V substrate for improved hip arthroplasty performance.
We also recommend Trading Suppliers and Manufacturers of phosphorylcholine (cas 107-73-3). Pls Click Website Link as below: cas 107-73-3 suppliers
Prev:Layer by layer assembled phosphorylcholine (cas 107-73-3) groups on paclitaxel/chitosan nanofibers coatings for hemocompatibility improvement
Next:ProtocolsBiocompatible zwitterionic phosphorylcholine (cas 107-73-3) polymers with aggregation-induced emission feature) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine (cas 107-73-3)08/26/2019
- In situ surface modification on dental composite resin using 2-methacryloyloxyethyl phosphorylcholine (cas 107-73-3) polymer for controlling plaque formation08/25/2019
- ProtocolsBiocompatible zwitterionic phosphorylcholine (cas 107-73-3) polymers with aggregation-induced emission feature08/24/2019
- Layer by layer assembled phosphorylcholine (cas 107-73-3) groups on paclitaxel/chitosan nanofibers coatings for hemocompatibility improvement08/22/2019
- Bioinspired mimics: Self-assembly of redox-activated phosphorylcholine (cas 107-73-3)–based biodegradable copolymers for enhancing antitumor efficiency08/21/2019
- Regular ArticleBiodegradable phosphorylcholine (cas 107-73-3)-based zwitterionic polymer nanogels with smart charge-conversion ability for efficient inhibition of tumor cells08/20/2019
- Role of phosphorylcholine (cas 107-73-3) in Streptococcus pneumoniae and nontypeable Haemophilus influenzae adherence to epithelial cells☆08/19/2019
- The therapeutic potential of tuftsin-phosphorylcholine (cas 107-73-3) in giant cell arteritis08/18/2019


